AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05476718 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio taping
Description: Patients will be informed about the study on the first day of their hospitalization and the Introductory Information Form, Visual Analogue Scale, and Oswestry Disability Index will be filled in by the patients. 24 hours after the operation, 20 minutes of training will be given to the patient and their relatives on the use of a pedometer and home care, and the first tape will be applied. After discharge, the renewal of the bands will be carried out on the postoperative 1th- 5th-10th-15th days when the patients come to the hospital for post-op evaluation. The clinical recovery of the operation area will be done by the investigative physician. In the follow-ups, evaluations will be made with the Visual Analog Scale, Medication Tracking Form, Oswestry Disability Index,Functional Low Back Pain Scale, Kinesio Tracking Form, and Gait Tracking Form.
Study NCT05476718 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo taping
Description: Patients will be informed about the study on the first day of their hospitalization and the Introductory Information Form, Visual Analogue Scale, and Oswestry Disability Index will be filled in by the patients. 24 hours after the operation, 20 minutes of training will be given to the patient and their relatives on the use of a pedometer and home care, and the first tape will be applied. After discharge, the renewal of the bands will be carried out on the postoperative 1th-5th-10th-15th days when the patients come to the hospital for post-op evaluation. The clinical recovery of the operation area will be done by the investigative physician. In the follow-ups, evaluations will be made with the Visual Analog Scale, Medication Tracking Form, Oswestry Disability Index,Functional Low Back Pain Scale, Kinesio Tracking Form, and Gait Tracking Form.
Study NCT05719597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEP (Positive Expiratory Pressure)
Description: Group A containing 12 participants, will perform Positive expiratory pressure (PEP) technique for total 60 repetitions (15 repetitions 2 sets, twice) per a day (5 sessions/week and total 4 weeks).
Study NCT05719597 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IS (Incentive spirometry)
Description: Group B containing 12 participants, will perform Incentive spirometry technique for total 60 repetitions (15 repetitions 2 sets, twice) per a day (5 sessions/week and total 4 weeks).
Study NCT05267002 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suture removal timing
Description: Cutaneous nylon suture removal of each half of the split-scar at one and two weeks.
Study NCT05099211 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscle biopsies
Description: Optional~In pre-training:~Biopsy performed during the digestive surgery procedure~Final evaluation (minimum 1 day and maximum 7 days after the last training session): biopsy performed in the digestive surgery department.
Study NCT05099211 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle Strengthening
Description: 3 sessions per week for 18 weeks. Duration: 1 hour Training on different strength training machines for the main muscle groups of the lower and upper limbs. The training load will be gradually increased over the sessions.
Study NCT05099211 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood and urine samples
Description: fasting blood sample taken at assessments 1, 2, 3 and 4 for patients and assessment 1 for controls
Study NCT05099211 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood and urine samples
Description: fasting blood sample taken at assessments 1, 2, 3 and 4 for patients and assessment 1 for controls
Study NCT05099211 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Training
Description: 3 sessions per week for 18 weeks. Duration: 1 hour Training on a classic pedal bicycle (called an ergocycle). The intensity and duration of the training will be gradually increased over the sessions and according to the patient's abilities.
Study NCT05099211 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation 1 pre-surgery
Description: Carried out at least 15 days before surgery~1. st visit:~   * Nutritional assessment~  * Body composition~  * Psychometric tests of quality of life + IPAQ Test~  * VO2pic~2. nd visit:~   * Neuromuscular tests~  * Functional tests
Study NCT05099211 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation 1 pre-surgery
Description: Carried out at least 15 days before surgery~1. st visit:~   * Nutritional assessment~  * Body composition~  * Psychometric tests of quality of life + IPAQ Test~  * VO2pic~2. nd visit:~   * Neuromuscular tests~  * Functional tests
Study NCT05099211 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation 2 post-surgery
Description: 1. st visit:~   * Body composition~  * Nutritional assessment~  * Psychometric tests of quality of life~2. nd visit:~   * neuromuscular tests~  * Functional tests~  * Familiarization with training equipment if patient participates in re-training
Study NCT05099211 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermediate Evaluation 3
Description: performed 9 weeks after the beginning of training Identical tests to evaluation 1 + TM6
Study NCT05099211 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Final post-training evaluation 4
Description: Tests identical to evaluation 1 + TM6
Study NCT06666049 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Gastric Ultrasound
Description: Gastric Ultrasound
Study NCT06665932 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy
Description: Stereotactic surgery is a minimally invasive form of surgical intervention that makes use of a three-dimensional coordinate system to locate small targets inside the body and to perform on them some action such as ablation, biopsy, lesion, injection, stimulation, implantation, radiosurgery, etc.
Study NCT05521477 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SLAB51
Description: One dose of probiotic consists of a bag of probiotic powder to dissolve in a glass of water according to the manufacturer instructions. Each bag contains 100 billion bacteria of the following strains: streptococcus thermophilus DSM 32245, 2 Bifidobacteria lactis DSM 32246 and DSM 32247, Lactobacillus acidophilus DSM 32241, Lactobacillus helveticus DSM 32242, Lactobacillus paracasei DSM 32243, Lactobacillus plantarum DSM 32244 and Lactobacillus brevis DSM 27961.
Study NCT05339061 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular Treatment of Complex abdominal or Thorocoabdominal aneurysms (TAAA).
Description: Modification~* Deploy the graft on the sterile, surgical table~* Mark out on the graft the locations of the fenestrations on the graft adjusting as necessary~* Using handheld electrocautery, fashion the fenestration in the appropriate location on the moistened graft material in order to prevent inadvertent progression of the fenestration size~* If the fenestration is going to remain as such, then a snare is used to fashion the marker on the fenestration with 5-0 stitch~* If the fenestration is going to be made into a branch, then an appropriately sized, self-expanding stent is beveled and fashioned to be 15 mm long and sewn to the fenestration in addition to a snare with the 5-0 stitch~* Two orientation markers are placed at the proximal edge and distal edge of the graft consisting of portions of the snare sewn to the anterior portion of the graft in a J fashion with a 5-0 stitch
Study NCT05099406 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial electrical stimulation
Description: By applying a low current over the cortex through the scalp, this technique can excite or inhibit the neural activity, thus modulating brain processes like pain perception and inducing relatively sustained changes in cortical excitability and neuroplasticity.~Home-based transcranial electrical stimulation device consists of a custom headgear with fixed electrode sites and built-in cabling made for a simplistic setup for tDCS/tACS stimulation. Systems are equipped with strict dose control feature that provide reliable control over the intensity and timing of stimulation, turning these devices into a feasible and safe clinical alternative. The equipment is specifically designed for easy and simplistic self-setup and allows the researchers to remotely check the position of electrodes and also monitor the stimulation session.
Study NCT05099406 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial electrical stimulation
Description: By applying a low current over the cortex through the scalp, this technique can excite or inhibit the neural activity, thus modulating brain processes like pain perception and inducing relatively sustained changes in cortical excitability and neuroplasticity.~Home-based transcranial electrical stimulation device consists of a custom headgear with fixed electrode sites and built-in cabling made for a simplistic setup for tDCS/tACS stimulation. Systems are equipped with strict dose control feature that provide reliable control over the intensity and timing of stimulation, turning these devices into a feasible and safe clinical alternative. The equipment is specifically designed for easy and simplistic self-setup and allows the researchers to remotely check the position of electrodes and also monitor the stimulation session.
Study NCT05023889 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: patisiran
Description: Patients will receive 0.3 mg/kg patisiran once every 21 days administered as an IV infusion over 70 minutes (approximately 1 mL/minute for the first 15 minutes followed by approximately 3 mL/minute for the remainder of the infusion) by a controlled infusion device.~All patients in this study will be premedicated prior to dosing with patisiran. Study drug supplied for this study must not be used for any purpose other than the present study and must not be administered to any person not enrolled in the study.~The first dose of study drug (week 1) will be administered under the supervision of site personnel. After the first dose of patisiran, patients should return to the site for patisiran dosing once every 21 days or receive the patisiran infusions at a local infusion center by a healthcare professional trained on the Protocol, administration of premedication, and patisiran infusion. Patient must receive a dose of interventional drug within the dosing window (±3 days).
Study NCT05586087 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: The High-Speed Resistance Training program has 16 weeks, with three sessions per week with 50-60min, each session being comprised of five-six exercises, two-three sets, and six-ten reps/exercise. The intensity is gradually increased after each session in accordance with the movement velocity (>1.3 to 0.75 m/s) representing approximately 20% to 60% of one repetition maximum. Participants execute the exercises rapidly and explosively making all repetitions for each shortening phase (concentric phase) performed as quickly as possible with the lengthening phase of the muscle (eccentric phase) being controlled for 2-3 s. The velocity of the concentric phase in each exercise is monitored through a BEAST™ sensor (Beast Technologies, Brescia, Italy).
Study NCT06523946 — intervention group
Intervention type: BEHAVIORAL
Intervention: Diabetes Prevention Program (DPP) (shortened)
Description: The investigators will adapt the protocol of the 'Ohana project. The 'Ohana protocol was developed based on CDC's Diabetes Prevention Program (DPP) curriculum and designed to fit PcI's cultural background. It includes a 8-lesson curriculum delivered in 8 weeks (shortened from the original 16-lesson, 24-week core curriculum of DPP while retaining all original foci and behavior change strategies). Specifically, the first four lessons, delivered every week, focus on getting the participants started on increasing PA and improving diet (e.g., introduction; getting started on PA and diet; utilizing goal setting; making the process fun). The second four classes will be taught every other week and will focus on how to handle various challenges involved in maintaining healthy lifestyle behaviors. The investigators will deliver the curriculum in group settings of 15 people in a separate room in the National Tongan American Society.
Study NCT05442892 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise training programme
Description: The supervised multicomponent exercise training programme will be comprised of upper and lower body strengthening exercises, tailored to the individuals functional capacity, using weight machines and aiming for 2-3 sets of 8-10 repetitions at an intensity of 30-60% of 1RM (Matrix, Johnson Health Tech, Ibérica, S.L. Torrejón de Arroz, Madrid, Spain) combined with balance and gait retraining exercises that progressed in difficulty and functional exercises such as rises from a chair.
Study NCT05179395 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brasthesis
Description: Brasthesis is a harness that is integrated with an off the shelf sports bra
Study NCT05698212 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MetriDx
Description: Biopsied tissue will be analyze by proprietary LDT, MetriDx, and compared to laparoscopy diagnostic report on record
Study NCT05698212 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MetriDx
Description: Biopsied tissue will be analyze by proprietary LDT, MetriDx, and compared to laparoscopy diagnostic report on record
Study NCT06190015 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Advanced platelet rich fibrin (APRF) clots
Description: 15 minutes before surgery, phlebotomy will be performed and two vacutainers containing 10ml of blood will be placed in the centrifuge for 8 min and 200g. Acquired APRF clots will be placed in the extraction alveolus
Study NCT06190015 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Enamel matrix derivative (EMD) group
Description: After third molar removal, Pref Gel (EDTA) will be placed on the root surface for 2 min and then removed. Emdogain (EMD) will be placed on the collagen sponge (Botiss, Collacone) and then applied in the wound so that the side of the sponge which is covered with Emdogain is in contact with the root surface.
Study NCT05377671 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: IRM multimodale a ultra-haute camp
Description: The MRI includes, in addition to structural task sequences, diffusion imaging and resting state fMRI.
Study NCT06433011 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Bashir™ Endovascular Catheter
Description: The Bashir™ Endovascular Catheter is a device intended for the localized infusion of therapeutic agents into the pulmonary artery and peripheral vasculature.
Study NCT06433011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: r-tPA
Description: Pulse spray and infusion
Study NCT06107673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib
Description: Dalpiciclib: Take 125 mg once daily for 3 weeks, then stop for 1 week. Each cycle is completed in 4 weeks. It is recommended to take the medication approximately at the same time each day, with warm water, preferably on an empty stomach. Fasting for at least 1 hour before and after medication is advised.
Study NCT06107673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor
Description: AI: Take according to the instructions provided.
Study NCT06107673 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel injection
Description: Administered as a 75 mg/m2 intravenous infusion over approximately 30 minutes. It is given every three weeks and dose reduction or treatment delay is allowed, up to a maximum delay of 3 weeks from the previous dose calculation. Treatment will be terminated if the delay exceeds this limit.
Study NCT06107673 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin Hydrochloride Injection
Description: Administered as a 75 mg/m2 intravenous infusion. It is given every three weeks and dose reduction or treatment delay is allowed, up to a maximum delay of 3 weeks from the previous dose calculation. Treatment will be terminated if the delay exceeds this limit.
Study NCT06107673 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide injection
Description: Administered as a 500 mg/m2 intravenous infusion. It is given every three weeks and dose reduction or treatment delay is allowed, up to a maximum delay of 3 weeks from the previous dose calculation. Treatment will be terminated if the delay exceeds this limit.
Study NCT05337748 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lexie Self Test and Fit Group
Description: The intervention offered is a hearing aid fitting with Lexie Lumen hearing aids coupled with a slimtube and dome. The hearing aids will be accompanied and operated using the Lexie smartphone application. Participants will self-perform an in-situ hearing check (pure tones presented via the hearing aids). The prescriptive gain of the hearing aids will be programmed and applied automatically using the obtained in-situ hearing thresholds. Participants will be fitted according to the customized, Lexie optimal fit prescribed gain setting. The optimal settings include the original gain and compression requirements that NAL-NL2 suggests for various audiograms. No additional band equalizer or compression adjustments are added. After a specified period of time, participants will be able to self-adjust the hearing aids using the smartphone application.
Study NCT05337748 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lexie Professional Test and Fit Group
Description: The intervention offered is a hearing aid fitting with Lexie Lumen hearing aids coupled with slimtube and dome. Hearing aids will be fitted by a certified audiologist according to a gold-standard prescriptive formula (NAL-NL2) using a clinically obtained diagnostic pure tone audiogram. Participants will have access to the smartphone application, but the settings will be limited with only options to change the volume of the hearing aids.
Study NCT05432206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis Sativa Oil
Description: Cannabis Sativa oil standardized: 11 mg THC/g and 22 mg CBD/g.
Study NCT05432206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Hemp virgin seed oil
Study NCT04692155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: Ublituximab (900mg) will be administered as an intravenous infusion through a dedicated line.
Study NCT04692155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbralisib
Description: Umbralisib(800mg)will be administered orally once daily within 30 minutes of starting a meal.
Study NCT04602754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BERLIM 25/20 ASSOCIATION
Description: Berlim 25/20 association coated tablet.
Study NCT04602754 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMPAGLIFLOZIN PLACEBO
Description: Empagliflozin placebo coated tablet.
Study NCT04602754 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ROSUVASTATIN CALCIUM PLACEBO
Description: Rosuvastatin calcium placebo coated tablet.
Study NCT04602754 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMPAGLIFLOZIN
Description: Empagliflozin 25 mg coated tablet.
Study NCT04602754 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ROSUVASTATIN CALCIUM
Description: Rosuvastatin 20 mg coated tablet.
Study NCT04602754 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BERLIM 25/20 ASSOCIATION PLACEBO
Description: Berlim 25/20 association placebo coated tablet.
Study NCT05471596 — intervention group
Intervention type: DEVICE
Intervention: NeuWave Microwave Ablation System
Description: The NEUWAVE System supports target ablation or linear coagulation in surgical liver resection procedures. The System offers a versatile probe portfolio, multi-probe synchrony and CO2 cooling to help control the shape, size and burn pattern of your ablations.
Study NCT04902872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBX-12
Description: CBX-12 is an alphalex construct which consists of a low-pH insertion peptide, a self-immolating linker, and exatecan as the pharmacologically active moiety
Study NCT06585982 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Treatment
Description: RILLUS is a synbiotic produced by Kalbe Farma
Study NCT06585982 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Placebo produced by Kalbe Farma
Study NCT06589297 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Modified Rankin scale
Description: Acute stroke patients will undergo modified rankin scale
Study NCT06589778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A2102
Description: SHR-A2102: injection, 80mg/ bottle, intravenous drip
Study NCT06589778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebelimab (SHR-1316)
Description: Adebelimab (SHR-1316): injection, 600mg(12mL)/ bottle, intravenous drip
Study NCT06589778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-8068
Description: SHR-8068: injection, 50mg（10mL）/ bottle, intravenous drip
Study NCT05786040 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT05786040 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT05786040 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT05786040 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET
Study NCT05786040 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV or SC
Study NCT05786040 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Given IV